11 Results for "

Myc-1

" in MedChemExpress (MCE) Product Catalog:
Products (11)

11 Results for "Myc-1" in MCE Product Catalog:

  • Targets Recommended:
5
5 Cited Publications
Cat. No.: HY-100669
CAS No.: 944547-46-0
Purity:  98.11%
Target:  

c-Myc Autophagy

Research Areas:  

Cancer

Mycro 3 is an orally active, potent and selective inhibitor of Myc-associated factor X (MAX) dimerization. Mycro 3 also inhibit DNA binding of c-Myc . Mycro 3 could be used for the research of pancreatic cancer .
loading...
    loading...
Cat. No.: HY-12863
CAS No.: 1380087-89-7
Purity:  99.95%
Synonyms: CPI-0610
Research Areas:  

Cancer

Pelabresib (CPI-0610) is a potent, selective, orally active and cell-active BET inhibitor. Pelabresib inhibits BRD4-BD1 with an IC50 of 39 nM, and with an EC50 value of 0.18 μM for MYC .
loading...
    loading...
Cat. No.: HY-134333
CAS No.: 2041072-41-5
Purity:  99.43%
Target:  

Apoptosis

Research Areas:  

Cancer

ICCB280 is a potent inducer of C/EBPα. ICCB280 exhibits anti-leukemic properties including terminal differentiation, proliferation arrest, and apoptosis through activation of C/EBPα and affecting its downstream targets (such as C/EBPε, G-CSFR and c-Myc) .
loading...
    loading...
Cat. No.: HY-147651
CAS No.: 2353536-67-9
Purity:  99.84%
Target:  

β-catenin CDK c-Myc

Research Areas:  

Cancer

β-catenin-IN-4 (Compound 39) is a β-catenin inhibitor with a Ki of 0.64 μM. β-catenin-IN-4 reduces the protein expression levels of cyclin D1 and c-Myc .
loading...
    loading...
Cat. No.: HY-178039
Research Areas:  

Cancer

CDK9-IN-42 is a potent and selective CDK9 inhibitor with an IC50of 3.8 nM. CDK9-IN-42 can inhibit the growth of cancer cells and induce apoptosis by downregulating Myc-1 and c-Myc. CDK9-IN-42 can be used for the research of cancer, such as breast and lungcancer [1].
loading...
    loading...
Cat. No.: HY-176488
CAS No.: 2034334-74-0
Research Areas:  

Cancer

Y-99 is a PORCN inhibitor with an IC50 of 155.4 nM against the Wnt/β-catenin signaling pathway. Y-99 inhibits the expression of p-LRP6, β-catenin, and c-Myc .
loading...
    loading...
Cat. No.: HY-149451
CAS No.: 2760195-67-1
Target:  

RET VEGFR c-Myc

Research Areas:  

Cancer

SYHA1815 is an orally active RET inhibitor (IC50=0.9 nmol/L) with antitumor activity. SYHA1815 is more selective for RET than KDR (IC50=15.9 nmol/L). SYHA1815 arrests the G1 cell cycle and inhibits RET-driven cell proliferation by downregulating c-Myc .
loading...
    loading...
Cat. No.: HY-150684
CAS No.: 3031654-49-3
Research Areas:  

Cancer

GXH-II-052 is a potent bivalent bromodomain and extraterminal domain (BET) inhibitor. GXH-II-052 shows binding potential for BRD4-1, BRD4-2, BRD4-T, BRDT-1, BRDT-2, BRDT-T with Kd values of 28, 9.1, 4.8, 0.6, 8.4, 2.6 nM, respectively. GXH-II-052 shows antiproliferative activity. GXH-II-052 decreases the expression of c-Myc .
loading...
    loading...
Cat. No.: HY-150683
CAS No.: 3031654-46-0
Research Areas:  

Cancer

NC-III-49-1 is a potent bivalent bromodomain and extraterminal domain (BET) inhibitor. NC-III-49-1 shows binding potential for BRD4-1, BRD4-2, BRD4-T, BRDT-1, BRDT-2, BRDT-T with Kd values of 0.095, 0.32, 0.29, 0.089, 5.5, 0.058 nM, respectively. NC-III-49-1 shows antiproliferative activity. NC-III-49-1 decreases the expression of c-Myc .
loading...
    loading...
Cat. No.: HY-100669R
CAS No.: 944547-46-0
Research Areas:  

Cancer

Mycro 3 (Standard) is the analytical standard of Mycro 3 (HY-100669). This product is intended for research and analytical applications. Mycro 3 is an orally active, potent and selective inhibitor of Myc-associated factor X (MAX) dimerization. Mycro 3 also inhibit DNA binding of c-Myc . Mycro 3 could be used for the research of pancreatic cancer .
loading...
    loading...
Cat. No.: HY-179734
Research Areas:  

Cancer

PROTAC BRD4 Degrader-41 (Compound A5) is a BRD4 PROTAC degrader with a DC50 of 0.97 nM. PROTAC BRD4 Degrader-41 exhibits potent anti-proliferative activity against various types of cancer cells such as AML, lymphoma, breast cancer, ovarian cancer, and non-small cell lung cancer. PROTAC BRD4 Degrader-41 can induce G0/G1 phase arrest and apoptosis in MV4-11 cells. PROTAC BRD4 Degrader-41 downregulates the transcriptional level of c-Myc .
loading...
    loading...
  • 1